Skip to main content
Premium Trial:

Request an Annual Quote

SW Michigan Life Science Fund Invests in Startup RealBio Technology

NEW YORK (GenomeWeb Daily News) – The Southwest Michigan First Life Science Fund said this week that it has invested an undisclosed amount in RealBio Technology to support the commercialization of its cell and tissue culture technology for drug discovery and life science research.

Other investors include stem-cell therapy firm Aastrom Biosciences and First Angels, a Kalamazoo-based angel investor group. RealBio also has received funding from the Michigan Pre-Seed Microloan Program.

RealBio's technology, called the Nth Degree system, creates an in vitro environment that mimics in vivo cell and tissue development, allowing researchers to study true organs and tissue in a laboratory setting, the company said. Applications of the technology include stem cell growth and collection, drug testing, and in vitro toxicology testing.

RealBio has a worldwide license to the patent-pending technology from Aastrom, which develops expanded autologous mixed-cell products for cardiac and vascular regeneration using its proprietary tissue repair cell technology platform. RealBio said that the licensed technology was developed by Aastrom researchers and is not competitive with the company's core cell therapy technologies.

In connection with the investment, Paul Neeb, executive in residence with the Southwest Michigan First Life Science Fund, has been named president and CEO of RealBio; while Lee Noll, who co-invented RealBio's technology while at Aastrom, has been named COO.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.